Hepatocellular Carcinoma Non-resectable Clinical Trial
Official title:
Cohort Study of Patients With Hepatocellular Carcinoma and Circulating Tumor DNA Monitoring of Chemoembolization
Cohort study to assess the impact of ctDNA detection in the follow-up and management of patients with hepatocellular carcinoma treated by TACE
The incidence of hepatocellular carcinoma (HCC) has increased significantly over the past 30 years. The majority of HCCs present at an intermediate stage, ineligible for a curative surgical approach and the reference treatment in this situation corresponds to a palliative locoregional treatment of Transarterial chemoembolization (TACE). This treatment modality can be repeated several times and the interval between each session as well as the modalities to evaluate the efficacy of this procedure remain poorly codified. This evaluation is currently based on imaging performed at one month (M1) (MRI and/or CT scan) more or less associated with the study of the variation of the alphafetoprotein level measured before (baseline) and after (M1) the treatment. However, these evaluation tools have many limitations and remain imperfect in predicting response to treatment. In this context, liquid biopsy, which is experiencing significant growth in oncology, could be a promising tool. It is characterized by the detection of tumor elements in the bloodstream such as circulating tumor DNA (ctDNA). Several studies have successfully demonstrated the diagnostic or prognostic value of ctDNA in patients followed for HCC. the aim of our study is to evaluate the impact of ctDNA detection in the follow-up of patients treated by TACE. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04592029 -
TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC
|
Phase 1 | |
| Recruiting |
NCT05953337 -
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
|
N/A | |
| Not yet recruiting |
NCT03283956 -
Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan
|
N/A | |
| Recruiting |
NCT03652467 -
The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma
|
Phase 1 | |
| Recruiting |
NCT05031949 -
Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma
|
Phase 1 | |
| Completed |
NCT03533920 -
Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma
|
N/A | |
| Recruiting |
NCT05992220 -
Atezolizumab Plus Bevacizumab Alone or Combined With External Beam Radiotherapy for HCC With Macrovascular Invasion
|
Phase 2 | |
| Not yet recruiting |
NCT05057104 -
Non-inferiority Study of Unresectable Hepatocelluar Carcinoma Receiving Stereotactic Radiotherapy Combined With Hepatic Arterial Chemoembolization Compared With Conversion Hepatectomy
|
||
| Completed |
NCT04599790 -
TACE Combined With Lenvatinib and Sintilimab for Advanced HCC
|
Phase 2 | |
| Completed |
NCT04599777 -
TACE Combined With Sorafenib and Tislelizumab for Advanced HCC
|
Phase 2 | |
| Recruiting |
NCT02967887 -
Evaluation of Hepatic Arterial Infusion of Cisplatin and 5-FU in Biomarker Stratified HCC
|
Phase 2 | |
| Recruiting |
NCT05608200 -
Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC
|
Phase 3 | |
| Recruiting |
NCT05608213 -
Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
|
Phase 3 | |
| Completed |
NCT04926376 -
Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable HCC and mCRC
|
N/A | |
| Recruiting |
NCT06133062 -
Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma
|
Phase 2 | |
| Completed |
NCT02989922 -
A Study to Evaluate SHR-1210 in Subjects With Advanced HCC
|
Phase 2 | |
| Recruiting |
NCT04273100 -
PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC
|
Phase 2 | |
| Completed |
NCT06408753 -
Plasma Biomarker in Predicting Response and Toxicity in HCC Patients Treated With Checkpoint Inhibitors With or Without SBRT
|
||
| Withdrawn |
NCT03563170 -
QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05713994 -
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
|